Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC518 phase 1 dose-escalation safety and pharmacokinetics study in healthy subjects
NL-OMON54972Phase 1Active, not recruiting
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of votoplam in Huntington disease (HD) (5 arms), sponsored by PTC Therapeutics, Inc. Primary endpoints: Safety and tolerability after single ascending dose, Safety and tolerability after multiple ascending doses and 3 more. Started Nov 2020; status: active, not recruiting.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON54972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54972.